|
|
|
Insider
Information: |
Powchik Peter |
Relationship: |
Director |
City: |
Tarrytown |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
251,572 |
|
Indirect Shares
|
4,133 |
|
|
Direct
Value |
$25,328,804 |
|
|
Indirect Value
|
$4,071,088 |
|
|
Total
Shares |
255,705 |
|
|
Total
Value |
$29,399,892 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Regeneron Pharmaceuticals Inc |
REGN |
SVP Clinical Developme... |
2016-05-16 |
25,714 |
2016-05-16 |
4,133 |
Premium* |
|
Vaxxinity, Inc. |
VAXX |
Director |
2022-03-31 |
225,858 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VAXX |
Vaxxinity, Inc. |
Director |
|
2022-03-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
225,858 |
|
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2016-05-16 |
4 |
GA |
$0.00 |
$0 |
I/I |
4,918 |
2,459 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2016-05-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,918 |
0 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2015-12-16 |
4 |
OE |
$52.03 |
$99,950 |
D/D |
1,921 |
17,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2015-08-14 |
4 |
S |
$569.63 |
$13,465,866 |
D/D |
(23,485) |
15,821 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2015-08-13 |
4 |
OE |
$30.63 |
$7,082,070 |
D/D |
60,361 |
41,702 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2015-08-13 |
4 |
D |
$579.35 |
$21,364,111 |
D/D |
(36,876) |
39,306 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2015-01-02 |
4 |
AS |
$410.99 |
$4,481,214 |
D/D |
(10,822) |
10,711 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2014-12-31 |
4 |
D |
$412.78 |
$5,852,395 |
D/D |
(14,178) |
21,533 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2014-12-31 |
4 |
OE |
$52.03 |
$1,300,750 |
D/D |
25,000 |
35,711 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2014-12-19 |
4 |
OE |
$30.63 |
$99,976 |
D/D |
3,264 |
10,711 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2014-01-02 |
4 |
AS |
$272.88 |
$5,678,965 |
D/D |
(20,668) |
25,447 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-31 |
4 |
D |
$276.09 |
$7,546,092 |
D/D |
(27,332) |
46,115 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-31 |
4 |
OE |
$30.63 |
$1,470,240 |
D/D |
48,000 |
73,447 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-24 |
4 |
OE |
$21.25 |
$99,981 |
D/D |
4,705 |
25,447 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-20 |
4 |
AS |
$271.09 |
$36,055 |
D/D |
(133) |
20,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-18 |
4 |
AS |
$270.20 |
$2,431,800 |
D/D |
(9,000) |
20,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-18 |
4 |
OE |
$21.25 |
$6,269 |
D/D |
295 |
21,037 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-18 |
4 |
D |
$264.86 |
$42,907 |
D/D |
(162) |
20,875 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-17 |
4 |
AS |
$270.00 |
$2,160 |
D/D |
(8) |
29,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-16 |
4 |
D |
$272.73 |
$5,895,604 |
D/D |
(21,617) |
29,750 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-16 |
4 |
OE |
$30.63 |
$3,281,056 |
D/D |
30,625 |
34,310 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-09 |
4 |
OE |
$16.80 |
$99,980 |
D/D |
5,752 |
20,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-03 |
4 |
AS |
$180.83 |
$2,474,091 |
D/D |
(13,586) |
14,990 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-02 |
4 |
D |
$177.82 |
$2,918,737 |
D/D |
(16,414) |
28,576 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|